|1.||Minkowitz, Harold S: 2 articles (11/2014 - 07/2013)|
|2.||Levy, Jerrold H: 2 articles (07/2013 - 07/2012)|
|3.||Sane, David C: 2 articles (07/2013 - 07/2012)|
|4.||Eriksson, B I: 2 articles (08/2012 - 07/2000)|
|5.||Smith, Jennifer R: 2 articles (12/2011 - 09/2011)|
|6.||Avidan, Michael S: 2 articles (12/2011 - 09/2011)|
|7.||Bartholomew, John R: 2 articles (01/2011 - 04/2010)|
|8.||Frame, James N: 2 articles (01/2011 - 04/2010)|
|9.||Rice, Lawrence: 2 articles (01/2011 - 04/2010)|
|10.||TIME Investigators: 2 articles (03/2005 - 06/2004)|
04/01/2010 - "Desirudin was administered as a fixed-dose injection (15 or 30 mg SC q12h in patients without or with thrombosis, respectively). "
07/01/2008 - "Desirudin reduces the rate of microvenous thrombosis in a rat model."
01/01/1991 - "The effects of recombinant desulphatohirudin on arterial thrombosis in rats."
02/28/1989 - "Venous stasis thrombosis was also highly susceptible to inhibition by CGP 39393 (ED50 = 0.01 mg/kg i.v. and 0.45 mg/kg s.c.). "
11/01/2014 - "Safety of desirudin in thrombosis prevention after total knee arthroplasty: the DESIR-ABLE study."
|2.||Venous Thrombosis (Deep-Vein Thrombosis)
09/01/2011 - "Desirudin: a review of the pharmacology and clinical application for the prevention of deep vein thrombosis."
11/13/1999 - "[Desirudine (Revasc): preventive therapy for deep venous thrombosis]."
09/01/2011 - "Desirudin was the first DTI approved for deep vein thrombosis (DVT) prophylaxis in Europe (Revasc®) and is the newest injectable DTI commercially available in the USA. "
09/01/2000 - "As a prophylaxis in patients undergoing hip replacement surgery, desirudin was significantly more effective in reducing the incidence of deep vein thrombosis (DVT) than either unfractionated or low molecular weight heparin. "
12/01/2011 - "Incidence of deep venous thrombosis was 4.9% and 3.4% in the desirudin and heparin groups, respectively. "
06/01/2001 - "Recombinant hirudins (such as desirudin) have been shown to be effective in the treatment of heparin-induced thrombocytopenia (HIT) and in the prevention of thrombotic complications after hip or knee surgery. "
01/01/2011 - "A randomized, open-label pilot study comparing desirudin and argatroban in patients with suspected heparin-induced thrombocytopenia with or without thrombosis: PREVENT-HIT Study."
04/01/2010 - "The goal of the present article was to provide an overview of the rationale and design of the PREVENT-HIT study, a randomized, prospective, open-label, active drug-controlled, exploratory trial comparing the clinical and economic utility of desirudin versus argatroban in patients with suspected heparin-induced thrombocytopenia (HIT), with or without thrombosis. "
04/01/2010 - "Rationale and design of the PREVENT-HIT study: a randomized, open-label pilot study to compare desirudin and argatroban in patients with suspected heparin-induced thrombocytopenia with or without thrombosis."
10/01/1999 - "Two recombinant hirudin preparations, Revasc (Novartis) and Refludan (Aventis), are available for postsurgical DVT prophylaxis and alternate anticoagulant use in patients with heparin-induced thrombocytopenia. "
04/01/1994 - "The purpose of this study was to assess the value of recombinant desulfatohirudin (hirudin) as adjunctive therapy to thrombolysis in acute myocardial infarction. "
09/01/2000 - "A significant reduction with desirudin compared with heparin in the incidence of death or non-fatal (re)infarction at 24 hours in patients with acute myocardial infarction (MI) was reported in the GUSTO (Global Use of Strategies to Open Occluded Coronary Arteries) IIb trial but not in the TIMI (Thrombolysis and Thrombin Inhibition in Myocardial Infarction) 9B trial. "
04/01/1994 - "A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial."
05/01/1996 - "Other than very minor local bleeding in some volunteers, IK-HIR02 was well tolerated. "
08/01/1994 - "A major bleeding event occurred in the first 3 patients receiving 40 mg CGP 39393 b.i.d. "
01/01/2011 - "Major bleeding occurred in 2 patients on argatroban and in none during desirudin treatment. "
05/01/1996 - "Recombinant desulphatohirudin variant 1 is an effective inhibitor of postoperative fibrin formation in a rabbit model and is not associated with an increased risk of intraoperative or postoperative bleeding at the tested dose. "
06/01/1993 - "The prolonged bleeding was evident both immediately, and 30 min after cessation of the infusion of hirudin (CGP 39393). "
|6.||Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)
|9.||Aspirin (Acetylsalicylic Acid)
|1.||Hip Replacement Arthroplasty (Total Hip Replacement)
|3.||Angioplasty (Angioplasty, Transluminal)